| Metric | Q3 2026 | Q3 2025 |
|---|---|---|
| Revenue | 0.3 | 0.4 |
| Profit before tax | -33.3 | -28.6 |
| Net income | -33.3 | -28.7 |
| EPS (diluted, $ a share) | $-0.19 | $-0.20 |
A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.
| Revenue, year on year | -19.6% |
|---|
10-Q filed with the SEC, NASDAQ: ABSI. Figures from the filing's XBRL data; summary written with AI assistance from the filing.
Absci Corp: key numbers
- Share price
- $7.47Close, Nov 16
- Market cap
- $1.29B
- Shares outstanding
- 172.75MLatest SEC cover page
- Sector
- Industrial Applications and Services
- Industry
- Services-Commercial Physical & Biological ResearchSIC 8731
Today's reference numbers, updated daily. Not a valuation or a recommendation.
More from Absci Corp
All →Absci Financial Results
Absci Corp reported third quarter 2026 financial results and provided updates on its generative AI-designed therapeutic pipeline. The company is on track to release interim proof-of-concept data for its ABS-201 program in pattern hair loss in December 2026 and plans to initiate a Phase 2 trial for endometriosis in mid-2027.
“As we approach our first look at proof-of-concept data for ABS-201 next month, followed by full data early next year, we are excited for the opportunity to potentially demonstrate our program's ability to stimulate hair regrowth in a convenient and durable way.”
Sean McClain, Founder and CEO
“As ABS-201 progresses through the clinic, we have begun building our commercial infrastructure to support this and potential future programs. In line with that strategy, we are thrilled to be welcoming Gerry Muhle to Absci as our Chief Commercial Officer, whose experience we believe will position ABS-201 and our expanding program pipeline for success.”
Sean McClain, Founder and CEO